NCT02800070View on ClinicalTrials.gov

Autologous Stem Cell Transplantation of Cells Engineered to Express Alpha-Galactosidase A in Patients With Fabry Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

April 30, 2024

Study Completion Date

April 30, 2024

Conditions
Fabry Disease
Interventions
BIOLOGICAL

Lentivirus Alpha-gal A transduced stem cells

Trial Locations (3)

Unknown

Alberta Children's Hospital, University of Calgary, Calgary

QE II Health Sciences Centre, Halifax

Princess Margaret Cancer Centre, Toronto

Sponsors

Collaborators (1)

Ozmosis Research Inc.
All Listed Sponsors
collaborator

Ozmosis Research Inc.

INDUSTRY

lead

University Health Network, Toronto

OTHER